Trust the FDA? Yeah, right. You’d have better luck believing in the goodwill of a starving shark.
In fact, the agency just pretty much admitted that they’ve thrown 6 million Alzheimer’s patients to the Big Pharma wolves.
You no doubt remember that new Alzheimer’s drug they just approved with great fanfare. It’s the first new med for the disease in a generation. Which sounds fantastic… at first.
The only trouble is there’s no evidence it actually works.
The feds vowed we would get that evidence “soon.” It’s just that the drug is so promising they simply had to rush it to market as quickly as possible. You know, so they could give patients access to this modern medical miracle.
Well, my friend, we’ve just learned that the whole thing was a sham. A smokescreen to distract those of us who were asking questions. Because the promised “evidence” isn’t coming anytime soon.
In fact, if the latest report is any indication, there’s a good chance we may NEVER get it.
The ugly truth about that Alzheimer’s drug approval
Aducanumab’s effectiveness is so questionable that two clinical trials ended early after the Alzheimer’s drug showed a clear lack of benefit. And the FDA’s own advisory panel flat-out rejected it.
Why wouldn’t they? When a drug flunks a study THAT badly, there’s clearly no saving it. Well, except the FDA stepped in and saved it anyway.
The agency approved the drug over the objections of its own expert panel. They say they made the controversial move because studies showed it can eliminate some of the damage that marks the disease.
But here’s the ugly truth. While that sounds good on paper, it’s essentially meaningless.
Because what really matters is that an Alzheimer’s drug leads to improvements to memory and cognition. At the very least, it should lead to a slower rate of decline. And tragically there’s no solid evidence of that yet.
The FDA said it would order the company manufacturing this wolf in sheep’s clothing to continue to study it even after the drug’s approval. But now we’re learning that might never happen.
The company has until at least 2030 to do that study. And according to the new report, no one really expects it to actually be completed by then.
Natural approaches could help battle memory loss
First, it may prove impossible to recruit anyone for a new trial of the Alzheimer’s drug. Since the med is now available by prescription, why would anyone who wants it risk getting a placebo?
Second, these kinds of dates slip by all the time. For example, the makers of one drug approved for a degenerative disease in 2016 had until 2021 to do their study proving it works.
Well, here we are in 2021, and guess what? The study still hasn’t even started. They’re now shooting for 2025. Right. And I’m shooting for a winning Lotto ticket.
And third, let’s face facts here. Now that the drug is approved, the company’s not exactly going to be motivated to hurry it up. Why rush it?
The study results could hurt their bottom line if it proves – yet again – that the Alzheimer’s drug doesn’t help with real-world outcomes such as slowing memory loss and cognitive decline. So I expect a lot of feet-dragging here.
Meanwhile, patients are left with no proven options. Not from the mainstream, anyway. But there are some promising therapies to be found in natural medicine.
Some studies, for example, have shown that a blend of vitamins B6, B12, and folic acid can slow the “brain shrink” linked to cognitive decline. There are even signs that, in some cases, the B combo may slow the memory loss the marks the condition.
Omega-3 fatty acids, curcumin, ginkgo biloba, huperzine a, grape seed extract, and green tea extract have shown promise battling memory loss. And detoxifying therapies such as chelation have too.
Plus, emerging research on so-called “zombie” cells has found that targeting senescent cells with natural senolytic compounds such as quercetin and fisetin could help us win the battle against all the so-called diseases of aging, including Alzheimer’s.
Speak to a naturopathic doctor to find the most promising natural solutions for you or your loved ones.